India’s Wockhardt Sees Profit Nosedive On The Weight Of Import Bans
This article was originally published in PharmAsia News
Wockhardt earnings reel from mounting regulatory actions from the U.S., UK and EU. Management pledges restructuring to put the company back on track, but no short-term relief is in sight.
You may also be interested in...
Unable To Manage Debts, India’s Wockhardt Calls For Financial Restructuring; Habil Khorakiwala Resigns As Managing Director
MUMBAI - After plunging into a veritable financial crisis due to high debt levels, India's pharmaceutical and biotechnology company Wockhardt has called for a financial debt restructuring through ICICI Bank
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.